









































Pa
ge

 
1



Pa
ge

 
1

American Journal of  
Chemistry and Pharmacy (AJCP)

Subclinical Hypothyroidism: A Review
Safaa Mohamed Matarid1*

Volume 2 Issue 2, Year 2023
ISSN: 2834-0116 (Online)

DOI: https://doi.org/10.54536/ajcp.v2i2.1594
https://journals.e-palli.com/home/index.php/ajcp

Article Information ABSTRACT

Received: April 21, 2023

Accepted: May 11, 2023

Published: May 12, 2023

Both the mother and the fetus are physiologically stressed out during pregnancy. The second 
most prevalent endocrine illness among pregnant women, behind diabetes mellitus, is 
thyroid disease. Several differences in the mother’s thyroid function are seen in the complete 
life cycle of  pregnancy, and thyroid dysfunction occurs from the mother’s inability to 
adjust to these physiological changes. The possibility for maternal and fetal outcomes can 
be extremely high when endocrine abnormalities like Hypothyroidism are present during 
pregnancy. The fetal development and perinatal outcomes can be significantly impacted 
by thyroid illness, which is frequent in women of  reproductive age. For the first part of  
pregnancy, the fetus depends on the mother’s thyroid hormone, which is essential for optimal 
fetal neurodevelopment. There is authentication of  an association between overt maternal 
Hypothyroidism and overt maternal hyperthyroidism. With higher obstetrical risks and 
negative impacts on the offspring’s cerebrospinal nervous system expansion, grey matter”, 
and neurocognitive potential. Treatment for overt thyroid disorders improves results. 
Subclinical maternal hypothyroidism can have a negative impact on a baby’s neurocognitive 
and obstetrical outcomes, despite conflicting findings. Subclinical Hypothyroidism has 
not yet been successfully treated. Pregnancy-related subclinical hyperthyroidism is easily 
tolerated. However, new research has revealed no improvement with levothyroxine treatment, 
indicating that thyroid autoantibodies alone might also affect foetal and neurodevelopmental 
outcomes.. The fetus may be impacted by several uncommon maternal genetic thyroid 
conditions, such as a TSH receptor mutation that causes hCG hypersensitivity or“thyroid 
hormone contrary. The thyroid”perform  a key function. For the best care, it is crucial 
to understand fetal health. Data was gathered from different search engines and databases 
such as; Google Scholar, Scopus, PubMed, Elsevier, Cochrane, Sage, Medline, and Web of  
Science. Numerous studies were selected from 2017-2022, using the keywords Subclinical 
Hypothyroidism, Hypothyroidism, pregnancy, fetal damage, risk factors, current challenges, 
thyroid hormone, and American thyroid association. The full texts of  the retrieved articles 
were made accessible.

Keywords
Subclinical Hypothyroidism, 
Age Group, Infertility, 
Pregnancy, Prevalence, Fetal 
Health, Morbidity

1 Department of  Internal Medicine, Mediclinic Al Ain Hospital, heikh Khalifa Bin Zayed St - next to Choithrams Supermarket, Abu  
  Dhabi - United Arab Emirates 
* Corresponding author’s e-mail: SafaaMatarid12@outlook.com

INTRODUCTION
The thyroid gland disease known as subclinical 
Hypothyroidism (SCH) is distinguished by increased 
TSH and normal FT3 and FT4 levels. The only approach 
to detect this illness is through biochemical testing 
due to the wide variety of  clinical presentations. The 
causes are similar to those of  overt Hypothyroidism; 
the most common is chronic autoimmune thyroiditis 
(Hashimoto’s thyroiditis), characterised by anti-thyroid 
peroxidase antibodies. Other causes include previous 
hyperthyroidism, postpartum thyroiditis, subacute 
thyroiditis, thyroid injury and inflammation from 
radiation, surgery, medication, and thyroid infiltration.
(Khan et al., 2017).
Pregnant women frequently have Hypothyroidism. The 
detection frequency, particularly in emerging India, for 
example, has not kept up with the severity of  the issue. 
During pregnancy, the mother’s thyroid function changes. 
There are several causes for these alterations.
Similarly inflation in thyroglobulin due to high-rise 
estrogen and human chorionic gonadotrophin, inflation 
in renal losses of  iodine due to inflation of glomerular 
filtration rate, During pregnancy, the need for iodine 

and the production of  thyroid hormone both increase 
by 50%. This is due to alterations in the peripheral 
metabolism of  maternal thyroid hormone and changes 
in iodine transport to the placenta (Pokhanna et al., 2017).
Pregnancy is a stress test for the thyroid that can lead to 
Hypothyroidism in women with a low thyroidal reserve 
or iodine shortage. Subclinical Hypothyroidism affects 
2-7% of  pregnant women, and overt Hypothyroidism 
affects 0.22 to 2.5% (Sakr & Sakr, 2020) (Mandel, 2004), 
(Syamala et al.). Retardation in neurodevelopment is a 
result of  maternal Hypothyroidism, particularly in the 
first trimester, and hinders cognitive growth (Wade & 
Mandel, 2018), ((Aravelli et al., 2022; Malti).
Making a clinical diagnosis of  hypothyroidism during 
pregnancy is difficult due to nonspecific features that may 
be masked by already present obstetric symptoms. Thyroid 
function testing is therefore required for the diagnosis 
of  subclinical Hypothyroidism. Since Hypothyroidism 
is easily managed by early diagnosis and medication, this 
could lessen the burden of  unfavorable maternal and 
fetal outcomes, which are extremely frequently seen.
Screening should ideally be done during prenatal testing or 
after a pregnancy is confirmed. There aren’t any national 

https://doi.org/10.54536/ajcp.v2i1.1594
https://journals.e-palli.com/home/index.php/ajcp


Pa
ge

 
2

https://journals.e-palli.com/home/index.php/ajcp

Am. J. Chem. Pharm. 2(2) 1-8, 2023

guidelines for treating thyroid dysfunction, and there 
are few statistics on its prevalence during pregnancy 
in India. The study aims to assess the prevalence and 
consequences of  thyroid malfunction, particularly 
Hypothyroidism in pregnancy.
According to reports, the prevalence of  SCH is 4–10% in 
adults. However, this varies according to the population, 
with more instances occurring in regions with enough 
iodine (Canaris et al., 2000). Even more patients who 
take thyroid drugs are affected (Abdurazzakova, 2021). 
Like other thyroid conditions, SCH is more prevalent 
in women than males and worsens with age. Every year, 
it’s likely that 2-5% of  SCH patients will develop overt 
Hypothyroidism (Abdurazzakova, 2021). According 
to the increase in serum TSH levels, there are typically 
two types of  SCH: mildly raised TSH levels (4.0–10.0 m 
IU/L) and severely increased TSH values (>10 m IU/L). 
However, the lower limit of  TSH that should be utilised is 
still debatable, with numerous studies employing different 
cutoffs. Most SCH patients (4–10 m IU/L) have lesser 
levels of  elevated TSH (Kim et al., 2017).
A collection of  conditions known as thyroid diseases 
damage the thyroid gland. The thyroid is a tiny, butterfly-
shaped gland that produces thyroid hormones on the 
front of  your neck (Cooper & Biondi, 2012). Nearly 
every organ in your body, including your heartbeat, is 
impacted by thyroid hormones because they regulate how 
your body uses energy (Farling, 2000).
Sometimes the thyroid produces these hormones in 
excess or insufficiently. Hyperthyroidism, a condition in 
which your body produces too much thyroid hormone, 
can make numerous bodily processes faster. The term 
hyper denotes an overactive thyroid. Learn more about 
pregnancy-related hyperthyroidism. Hypothyroidism, 
or having too little thyroid hormone, can slow down 
many bodily processes. Hypo denotes the under activity 
of  the thyroid. Learn more about pregnancy-related 
Hypothyroidism (Mullur et al., 2014). Thyroid hormones 
part in central nervous system development (Morreale 
de Escobar et al., 2000). Since the fetus does not begin 
manufacturing thyroid hormone until weeks 16 to 20, the 
maternal thyroid is the only source of  thyroid hormone 
in the early stages of  pregnancy (Morreale de Escobar et 
al., 2000).
By having frequent thyroid function testing and taking 
any medications your doctor prescribes, you can still have 
a safe pregnancy and preserve the health of  your unborn 
child if  you have thyroid issues (Shahid et al., 2018).
Pregnancy is crucial for women since it involves significant 
physiological changes. Today, it has been discovered 
that fetal programming has consequences beyond fetal 
development; as a result, poor prenatal programming 
significantly impacts the development of  most chronic 
diseases that threaten human life (Huang et al., 2017).
One of  the most frequent endocrine abnormalities 
during pregnancy is thyroid disease. The relationship 
between maternal thyroid dysfunction during pregnancy 
and unfavorable pregnancy outcomes and long-term 

health effects has drawn much attention over the past two 
decades (Korevaar et al., 2017). Understanding variations 
in thyroid function and the effects of  thyroid disease 
during pregnancy is extremely important, given the 
significance of  thyroid hormones for a healthy pregnancy 
and fetal development. Numerous short- and long-term 
negative effects on the health of  the mother and fetus are 
associated with overt thyroid problems. When detected 
and addressed at an early enough stage, the majority of  
these complications can be avoided. Uncertainty exists 
over whether maternal subclinical Hypothyroidism 
affects pregnancy or the subsequent cognitive growth of  
their offspring.

Practical Issues

Figure 1: Shows TSH levels and their symptoms

Figure 2: Shows the key practical issues with Thyroid 
hormones and with no thyroid hormones

METHODOLOGY 
To indicate the treatment outcomes of  Subclinical 
Hypothyroidism in different age groups and in during 
pregnancy, several recent studies, review articles, 
prospective studies, cross-sectional studies, and literature 
reviews, all published and peer-reviewed, were searched 
and considered. The area of  search was based on how 
effective is treatment with thyroxine in preventing 
morbidity in different age groups, treatment of  infertility 
due to subclinical Hypothyroidism, prevention of  fetal 
loss, and fetal brain damage.
This article is a review. Thus not all information on thyroid 

https://journals.e-palli.com/home/index.php/ajcp


Pa
ge

 
3

https://journals.e-palli.com/home/index.php/ajcp

Am. J. Chem. Pharm. 2(2) 1-8, 2023

illness and its implications on fetuses has been provided 
are contained in this. We have included observational 
studies and all significant, pertinent big trials to highlight 
the overall conclusions. Although we tried to incorporate 
the largest and most pertinent research, it is important to 
keep in mind that the tiny, hopeful observational studies 
were likely chosen due to publication bias.

Physiology of  Thyroid During Pregnancy
Due to the increased metabolic demands during 
pregnancy, the thyroid gland undergoes considerable 
physiologic changes that affect its form and function. 
Depending on baseline iodine supplies, the thyroid 
expands by 0–30% in size when iodine requirements rise.
(Berghout & Wiersinga, 1998), (Vannucchi et al., 2017). 
Thyroid binding globulins (TBG), in particular, rise 2- to 
2.5-fold in response to increased serum estrogen (Sorrenti 
et al., 2021). The thyroid gland must produce more 
thyroid hormone to resist standard extent of  available 
thyroid hormone in response. Additionally, human 
chorionic gonadotropin (hCG) is released prematurely in 
pregnancy. It has an alpha subunit one is comparable to 
thyroid stimulating hormone’s (TSH) alpha subunit, this 
causes the thyroid gland to be directly stimulated, a rise in 
free thyroid hormone, and a reduction of  TSH in the first 
trimester of  pregnancy(ERDOĞAN et al., 2022; Glinoer 
et al., 1993). This is assumed to happen so the fetus 
receives enough available thyroid hormone to by pass  the 
placenta. Inlarged TBG, hCG stimulation, renal excretion, 
and transplacental transit of  available thyroxine (FT4)
cause a nearly 50% rise in thyroid hormone production 
during the first trimester (LeBeau & Mandel, 2006). 

Iodine and Conception
Iodine is a crucial element of thyroid hormones, and 
pregnant women need more of  it. Iodine shortage is 
linked to thyroid malfunction, affecting fetal development 
(Zimmermann, 2016). Today, it is generally acknowledged 
that severe maternal iodine deficiency can have negative 
effects on both the mother and the baby, including 
miscarriage and conditions including Hypothyroidism 
and goiter and stillbirth; for the newborn, including 
neonatal mortality; and for the child, including stunted 
growth, cretinism, and poor brain development (Delange, 
2007). In societies with severe iodine deficiency, iodine 
supplementation is advised as a treatment for maternal 
Hypothyroidism, and there is strong evidence that it 
improves clinical outcomes, such as rates of  cretinism 
and infant mortality (Li et al., 2016). Concerns have lately 
been voiced over the UK and other affluent nations iodine 
intake requirements for pregnant and childbearing women. 
Some formerly believed to be iodine-rich regions were 
mild to moderately iodine deficient (Zimmermann, 2007).
Additionally, recent research from the large longitudinal 
AVON project in the UK has indicated a linear 
relationship between mild-to-moderate maternal iodine 
shortage and worse cognition in children between the ages 
of  eight and nine (Bath et al., 2013). Despite the positive 

evidence, it is debatable whether pregnant women from 
areas with mild to moderate iodine deficiency should 
take iodine supplements. Concerning supplements, 
not all of  the research used rigorous techniques (Bath 
& Rayman, 2013). These studies have suggested that 
iodine supplementation in populations with mild-to-
moderate iodine deficiency may have some positive 
effects on maternal newborn serum thyroglobulin and 
thyroid volume (i.e., a smaller increase), though data on 
thyroid function are inconsistent, and there is a lack of  
hard evidence regarding long-term effects like pregnancy 
outcomes, childhood neurodevelopment, and growth 
(Zimmermann, 2007). Some research suggests that 
starting iodine supplementation sooner can lead to better 
results (Taylor et al., 2014).
The American Thyroid Association’s guidelines for 
diagnosing and treating thyroid disorders during 
pregnancy and postpartum served as the reference ranges 
for the test values used in this study. Regulation 14.2 of  
the ATA recommendations, states that the following 
normal reference ranges should be used in the laboratory 
in the absence of  trimester-specific TSH reference ranges 
in the laboratory.
“1st Trimester- 0.1 to 2.5 m IU/L”,
“2nd Trimester- 0.2 to 3m IU/L”,
“3rd Trimester- 0.3 to 3m IU/L”.
Standard free t4 volume is 0.7 to 1.8ng/ml
The free t3 volume is 1.7 to 4.2 pg/ml.

Thyroid Physiology in Fetus
In her opening remarks, Dr. Morreale de Escobar 
discussed the various neurodevelopmental consequences 
in infants born in regions with endemic iodine shortages 
and children born with inherited Hypothyroidism. 
Infants born to mothers severely deficient in iodine 
risk developing neurologic cretinism, which can cause 
psychological issues, deafness, mutism, squinting 
quadriplegia. If  these mental defective infants acquire 
enough iodine, their thyroid function will be completely 
normal at birth. On the other hand, infants with inherited 
Hypothyroidism are hypothyroid at birth and are thought 
to have been so while still in utero. However, babies born 
to moms who are iodine insufficient will suffer acute, 
irreparable brain damage originating by an event that 
occurred during the 1st  half  of  pregnancy, but neonates 
born with inherited Hypothyroidism, if  discovered 
and medicate in advance, will have a positive result for 
their neurodevelopment. Understanding fetal thyroid 
development and possible maternal thyroid rise to the 
fetus is necessary to explain these disparities, particularly 
in the first half  of  pregnancy, before the foetus develops 
any significant thyroid hormone (Eng & Lam, 2020).

First Trimester
Fetal thyroid hormone levels are determined by fetal 
coelomic fluid and serum.
The existence of thyroid hormone in the fetus during the 
1st  trimester has been shown in fetal coelomic fluid at 

https://journals.e-palli.com/home/index.php/ajcp


Pa
ge

 
4

https://journals.e-palli.com/home/index.php/ajcp

Am. J. Chem. Pharm. 2(2) 1-8, 2023

six weeks and fetal serums at twelve weeks of  gestation, 
which are probably of  maternal genesis (Contempré et 
al., 1993). 
Thyroid hormone levels in the circulation of  the fetus 
continue to rise throughout pregnancy, as sum-up here:

1. At 12 weeks gestation, the average foetal serum T4 
level is about 26 nmol/L, and at term, it is 128 nmol/L. 
Foetal serum-free T4 (fT4) levels climb over the course 
of  pregnancy, with a mean value of  around 1.3 pmol/L 
at 12 weeks and 25.7 pmol/L at duration. (Jansen et al., 
2019).

2. The total triiodothyronine (T3) and free T3 
concentrations in fetal serum remain low until 30 weeks 
of  gestation due to the placental inner deiodination 
process of  T4 to reverse triiodothyronine (rT3) and 
increase slowly from roughly 0.09 nmol/L at the 12th 
gestational week to 0.68 nmol/L at birth.

3. TBG concentrations also increase noticeably, rising 
from 5 mg/L during 12 weeks gestation to about 25 
mg/L at delivery, with higher concentrations in babies 
than in adults.
The research team led by Dr. Morreale de Escobar 
concluded that the levels of  thyroid hormone-binding 
proteins in fetal fluids and serum is extremely low and 
independent of  the maternal thyroid state. Before 
midgestation, most maternal T4 and T3 enter these 
compartments in the free form, causing levels to rise to 
physiologically important levels.
They suspect there is proof  that these maternal hormones 
play a significant role in fetal evolution, notably in the 
neurological structure, as is explained below. They also 
emphasize the importance of  placental barrier to stop 
free T4 and particularly T3 from entering the fetal tissues 
at extent, can be hazardous.

Iodothyronine Deiodinases in Fetuses
Physiology of  the fetal thyroid Thyroid hormones 
(TH) is produced by the mother during early pregnancy. 
Despite being first noticed at 10–12 weeks, fetal TH and 
hypothalamic-pituitary maturation do not start to rise 
until 18–20 weeks. The main fetal deiodinase that activates 
thyroid function is deiodinase type 2, or D2, which 
becomes more active by the end of  the first trimester and 
enhances thyroid receptor occupancy with T3. Apo-TRs: 
thyroid hormone receptors that are not occupied.

Second and Third Trimester
Thyroid Hormone Levels in Serum
Around 18 to 20 weeks of  gestation, the pituitary-
portal vascular system fully develops, and fetal thyroid 
hormone secretion starts. Foetal serum T4 rises without 
involvement of  maternal-fetal vascular connections from 
a mean of  around 2 g/dL (26 nmol/L) at 12 weeks to 
10 g/dL (138 nmol/L) at term in samples obtained via 
cordocentesis. (Ziegler et al., 2022). The rise in hepatic 
fabrication of  serum TBG and, to a minor  extent, the 
stimulation of  fetal thyroidal T4 production by TSH 
are both responsible for the rise in serum T4. From a 

mean of  roughly 0.1 ng/dL (1.3 pmol/L) at 12 weeks 
to 2.0 ng/dL (25.7 pmol/L) at term, fetal serum Due to 
placental type 3 or 5-deiodinase 3 (5-D3) venture, which 
changes T4 to reverse triiodothyronine (rT3) and T3 to 
reverse T2, the increase in fetal serum and free T3 levels 
is significantly less. Foetal serum T3 levels range from 
6 ng/dL (0.09 nmol/L) at 12 weeks to 45 ng/dL (0.68 
nmol/L) at term. Adult values of  euthyroid persons 
serum TSH levels are particularly execessive than in the 
maternal circulation, rising progressively from 4 mU/L 
at 12 weeks to 8 mU/L at term. It is well thought out 
that the genesis and evolution purpose of  this foetal TSH 
remain unknown. Because of  intrauterine levels of  free 
T4, it appears that the development of  the hypothalamic-
pituitary-thyroid compact and negative response is not 
finished prior a few months after birth. of  free T4 and 
TSH are favourably related up to delivery. The fact that 
intrauterine FT4 levels are significantly greater than the 
one found in age-paired preterm babies leads to the 
perspective that maternal transfer of   T4 continues to 
donate remarkably to the hormones accessible to foetal 
tissues (Ares et al., 1997), (Morreale de Escobar, 1998). 

Hypothyroidism
Primary maternal Hypothyroidism is characterised as a 
high TSH level throughout pregnancy without uncommon 
exceptions such as thyroid hormone resistance, pituitary 
tumors that secrete TSH, and a few cases of  central 
Hypothyroidism with physiologically inactive TSH 
(Zimmermann, 2007). 

Hypothyroidism and the Results of  Pregnancy 
(Overt Hypothyroidism)
Overt hypothyroidism has been associated with preterm 
birth, prenatal hypertension, placental abruption, 
low birth weight, postpartum hemorrhage, perinatal 
morbidity, and mortality. (Wasserstrum & Ananla, 1995). 
In overt Hypothyroidism, the probability of  preterm birth 
was higher (or 1.19, P 0.00001), according to a synopsis 
of  14th cohort studies and one case-control study 
(Sheehan et al., 2015). The risk of  problems was greatly 
reduced by earlier treatment of overt Hypothyroidism 
and normalisation of thyroid function during pregnancy 
(Leung et al., 1993).

Subclinical Hypothyroidism
Poor perinatal outcomes could also be made more likely 
by subclinical Hypothyroidism (Maraka et al., 2016). 
According to a synopsis of 18 cohort studies, women’s  
with subclinical Hypothyroidism had a inflated risk of  
miscarriage (RR 2.01), placental abruption (RR 2.14), 
preterm membrane breach (RR 1.43), and infant death 
(RR 2.58) (Maraka et al., 2016). Contrarily, a study 
of  10,990 patients found no increase in unfavorable 
pregnancy outcomes in the 483 (4.4%) women who 
had subclinical Hypothyroidism (TSH >97.5% , FT4 
2.5-97.5%) (Rosario et al., 2018). The variations in 
these studies findings could be attributed to the various 

https://journals.e-palli.com/home/index.php/ajcp


Pa
ge

 
5

https://journals.e-palli.com/home/index.php/ajcp

Am. J. Chem. Pharm. 2(2) 1-8, 2023

ways subclinical Hypothyroidism has been defined 
and the presence or absence of  TPO antibodies. The 
subclinical hypothyroidism definition used in the meta-
analysis varied between research studies; some adjusted 
for TPO status while others did not (Maraka et al., 2016). 
Positive antibodies raise the likelihood of  complications 
for women with subclinical hypothyroidism”, and 30- 60% 
of  pregnant women with high TSH have greater levels of  
TPO antibodies (Mansouri et al., 2017). As was previously 
mentioned, a meta-analysis of  three randomised trials that 
examined the influence of levothyroxine medication for 
subclinical Hypothyroidism did’nt find any differences in 
obstetrical consequences after 3, 5, or 9 years of  persue.
To summarise, gestational hypertension, squat birth 
weight, and premature delivery are all increased by overt 
maternal Hypothyroidism. Treatment, particularly in 
the early stages of  pregnancy, helps reduce these risks. 
Although the evidence is mixed, maternal subclinical 
Hy Additionally, the treatment’s results have not yet 
been observed. This may not come as a surprise given 
the biological improbability that even a very slight 
thyroid dysfunction would cause like a wide variety of  
unfavourable pregnancy outcomes.pothyroidism may 
also negatively impact obstetrical consequences.
There are conflicting recommendations about when to 
start treating subclinical Hypothyroidism. Currently, the 
American Thyroid Association advises starting treatment.
When a pregnant woman has subclinical Hypothyroidism, 
her TSH should be less than 4.0 mIU/L when the 
pregnancy-certain reference value is not accessible to 
their community, 2.5 mIU/L if  she has negative TPO 
antibodies”, and more than that if  she has positive 
TPO antibodies (Anagnostis et al., 2017). The American 
College of  Obstetricians and Gynaecologists states that 
there is no evidence that subclinical Hypothyroidism can 
be identified or treated and makes no recommendations 
about its management; pregnant women with 
subclinical Hypothyroidism have better baby outcomes 
(Obstetricians ACo, 2015). The Royal Australian and New 
Zealand College of  Obstetricians and Gynaecologists 
advises against testing for TPO antibodies or subclinical 
Hypothyroidism and against using levothyroxine to 
treat subclinical Hypothyroidism during pregnancy 
(James-McAlpine, 2019). The treatment of subclinical 
Hypothyroidism in the course of   pregnancy can not 
be necessary, according to the findings of  more recent 
investigations.

DISCUSSION
One of  the most prevalent endocrine conditions in 
pregnant women is thyroid disease, which negatively 
affects both the mother and the fetus. The initial antenatal 
visit’s universal screening aids in identifying thyroid 
problems in pregnancy. Thyroid dysfunction should 
ideally be screened for before conception because any 
hypothyroid status can be treated before trying for a baby.
This clinical study’s primary goal was to ascertain the 
frequency of  thyroid problems in pregnancy. Geographical 

differences in the prevalence of  Hypothyroidism during 
pregnancy are significant. According to data from Western 
nations, subclinical Hypothyroidism affects an estimated 
2.5% of  people, and overt Hypothyroidism complicates 
up to 0.3% of  pregnancies (AKBAŞ & ÇARLIOĞLU, 
2020). In India, pregnancy-related Hypothyroidism is 
significantly more common than in Western nations. 
We still have iodine deficiency in many areas of  India. 
Therefore prevalence varies greatly between different 
states. Iodine deficiency is the most typical cause of  
Hypothyroidism in pregnancy in underdeveloped nations 
like India.
According to the study, 6.8% of  people had 
Hypothyroidism, with 0.7% having overt Hypothyroidism 
and 6.1% having subclinical Hypothyroidism. Subclinical 
Hypothyroidism was shown to be prevalent in 633 
people in the Indian population in a prior study, which 
was carried out in 2010 (Sahu et al., 2010). Our data is 
on par with recent research on prevalence. According 
to the statistics gathered, pregnant women have a high 
frequency of  Hypothyroidism, which necessitates rapid 
intervention. This high prevalence may be caused by 
multiple pregnancies, adolescent pregnancies, the low 
nutritional content of  local foods, malnutrition and 
iodine deficiency, poor socioeconomic conditions of  
the local population, and high physiological demand 
during the growing years. In addition to iodine shortage, 
environmental factors may contribute to the prevalence 
of  Hypothyroidism in the area.
Compared to the West, Asian countries were found to have 
a higher prevalence of  Hypothyroidism. The prevalence of 
Hypothyroidism was considerably higher in the high-risk 
group than in the non-high-risk group in a huge Chinese 
research study that collectively 2899 pregnant women (10.9 
vs. 7.0%, P = 0.008) (Ayyar, 2011).
According to a Chinese study, goitrogens are present 
in the food, as evidance from India, and micronutrient 
deficiencies, like those in selenium or iron, might result in 
Hypothyroidism and goiter (Marwaha et al., 2003) (Teng 
et al., 2011), (Das et al., 2011).
Therefore, it is hypothesized that India and Asia have 
greater rates of  Hypothyroidism during pregnancy. In 
India, Hypothyroidism is also not consistently prevalent 
(Gayathri et al., 2009). Bandela et al. 10% of  people in 
Andhra Pradesh reported having SCH.
2.8% of  people had SCH, according to Gayathri et al. 
TSH’s varying upper limit cutoffs could contribute to this 
discrepancy (Unnikruishnan et al., 2013).

Rate of  Live Births Per Cycle
“Using data from nine studies involving 4396 women, 
Busnelli et al. discovered that women with positive 
TAI had lower LBR than women with negative TAI 
(OR 0.73, 95% CI [0.54-0.99], p14.04). The pooled 
effect estimate was also obtained using a random effect 
(notmod0.64, 950.64,90.42-0.99], p 14.05).Werhofer et al. 
discovered that low TSH levels were linked to a higher 
likelihood of  getting pregnant (13.9%) as opposed to 

https://journals.e-palli.com/home/index.php/ajcp


Pa
ge

 
6

https://journals.e-palli.com/home/index.php/ajcp

Am. J. Chem. Pharm. 2(2) 1-8, 2023

high TSH levels, which were linked to a lower likelihood 
of  getting pregnant (5%); however, the authors note 
that statistical analysis of  the link between baseline 
TSH levels and pregnancy potential was not possible in 
their study because of  the small sample size (2-0.99], p. 
14.05).“Werhofer et al.’s”observation towards upgraded 
pregnancy potential in the presence of  low-normal TSH 
levels (13.9%) compared to the high-normal TSH group 
(5%), but the authors note that statistical analysis of  the 
effect of  baseline TSH levels on pregnancy potential 
was not possible in their research  study due to the least 
number of pregnancies’. 

CONCLUSION
To prevent harmful results for the mother and fetus, 
thyroid dysfunction during pregnancy must be identified 
and treated early. Both overt Hypothyroidism need to 
be properly managed. Levothyroxine is frequently used 
to treat subclinical Hypothyroidism; however, its ability 
to improve maternal or fetal outcomes has not been 
conclusively demonstrated. Treatment for subclinical 
hyperthyroidism is typically unnecessary, although it 
should be remembered that nonthyroidal disease or 
pregnant thyrotoxicosis are both possibilities. Although 
monitoring studies with euthyroid women who had 
thyroid autoantibodies showed worse maternal and fetal 
outcomes, there is currently insufficient evidence to 
show that these outcomes are improved by thyroxine 
supplementation. More RCTs are required to examine 
the effects of  treating pregnant euthyroid women with 
autoimmune thyroid disease, subclinical hypothyroidism, 
and isolated hypothyroxinemia. A secure basis for practise 
is provided by current practise guidelines, and they are 
strikingly similar and differing in significant ways that 
generally point to gaps in our present understanding of  
thyroid problems in pregnancy.

REFERENCES
Abdurazzakova, D. (2021). Subclinical Hypothyroidism in 

Women in the Andijan Region. National Association of  
Scientists, 2(74), 22-25. 

Akbaş, E. M., & Çarlioğlu, A. (2020). Vakalarla Tiroid 
Hastalıkları. Akademisyen Kitabevi. 

Anagnostis, P., Lefkou, E., & Goulis, D. G. (2017). Re: 
Guidelines of  the American Thyroid Association for 
the diagnosis and management of  thyroid disease 
during pregnancy and the postpartum by Alexander 
et al. Thyroid, 27(9), 1209-1210. 

Aravelli, L., Meduri, A. A., Rallabhandi, S., & Srilakshmi, 
K. (2022). Prevalence of  overt and subclinical thyroid 
dysfunction in pregnant women and outcome in a 
tertiary care centre. ScienceRise: Medical Science, 5(50), 
16-23. 

Ares, S., Escobar-Morreale, H. C. F., Quero, J., Durán, S., 
Presas, M. a. J., Herruzo, R., & Morreale de Escobar, 
G. (1997). Neonatal hypothyroxinemia: effects of  
iodine intake and premature birth. The Journal of  
Clinical Endocrinology & Metabolism, 82(6), 1704-1712. 

Ayyar, V. S. (2011). History of  growth hormone therapy. 
Indian Journal of  Endocrinology and Metabolism, 15(l3), 
162. 

Bath, S. C., & Rayman, M. P. (2013). Iodine deficiency 
in the UK: an overlooked cause of  impaired 
neurodevelopment? Proceedings of  the Nutrition Society, 
72(2), 226-235. 

Bath, S. C., Steer, C. D., Golding, J., Emmett, P., & 
Rayman, M. P. (2013). Effect of  inadequate iodine 
status in UK pregnant women on cognitive outcomes 
in their children: results from the Avon Longitudinal 
Study of  Parents and Children (ALSPAC). The Lancet, 
382(9889), 331-337. 

Berghout, A., & Wiersinga, W. (1998). Thyroid size 
and thyroid function during pregnancy: an analysis. 
European Journal of  Endocrinology, 138(5), 536-542. 

Canaris, G. J., Manowitz, N. R., Mayor, G., & Ridgway, E. 
C. (2000). The Colorado thyroid disease prevalence 
study. Archives of  Internal Medicine, 160(4), 526-534. 

Contempré, B., Jauniaux, E., Calvo, R., Jurkovic, D., 
Campbell, S., & De Escobar, G. M. (1993). Detection 
of  thyroid hormones in human embryonic cavities 
during the first trimester of  pregnancy. The Journal of  
Clinical Endocrinology & Metabolism, 77(6), 1719-1722. 

Cooper, D. S., & Biondi, B. (2012). Subclinical thyroid 
disease. The Lancet, 379(9821), 1142-1154. 

Das, S., Bhansali, A., Dutta, P., Aggarwal, A., Bansal, 
M., Garg, D., Ravikiran, M., Walia, R., Upreti, V., & 
Ramakrishnan, S. (2011). Persistence of  goitre in the 
post-iodization phase: micronutrient deficiency or 
thyroid autoimmunity? The Indian Journal of  Medical 
Research, 133(1), 103. 

Delange, F. (2007). Iodine requirements during pregnancy, 
lactation and the neonatal period and indicators of  
optimal iodine nutrition. Public Bealth Nutrition, 10(12), 
1571-1580. 

Eng, L., & Lam, L. (2020). Thyroid function during the 
fetal and neonatal periods. Neoreviews, 21(1), 30-36. 

Erdoğan, M., Bayramova, G., Özişik, H., & Suner, A. 
(2022). Investigation on Demographic Characteristics 
of  Pregnant Patients with Thyroid Dysfunction-Ege 
University Sample. Batı Karadeniz Tıp Dergisi, 6(3), 
345-351. 

Farling, P. A. (2000). Thyroid disease. British Journal of  
Anaesthesia, 85(1), 15-28. 

Gayathri, R., Lavanya, S., & Raghavan, K. (2009). 
Subclinical hypothyroidism and autoimmune 
thyroiditis in pregnancy--a study in south Indian 
subjects. The Journal of  the Association of  Physicians of  
India, 57, 691-693. 

Glinoer, D., De Nayer, P., Robyn, C., Lejeune, B., 
Kinthaert, J., & Meuris, S. (1993). Serum levels of  
intact human chorionic gonadotropin (HCG) and its 
free a and β subunits, in relation to maternal thyroid 
stimulation during normal pregnancy. Journal of  
Endocrinological Investigation, 16, 881-888. 

Huang, H., Rusiecki, J., Zhao, N., Chen, Y., Ma, S., Yu, 
H., Ward, M. H., Udelsman, R., & Zhang, Y. (2017). 

https://journals.e-palli.com/home/index.php/ajcp


Pa
ge

 
7

https://journals.e-palli.com/home/index.php/ajcp

Am. J. Chem. Pharm. 2(2) 1-8, 2023

Thyroid-Stimulating Hormone, Thyroid Hormones, 
and Risk of  Papillary  Thyroid Cancer: A Nested 
Case–Control Study TSH, Thyroid Hormone, and 
PTC. Cancer Epidemiology, Biomarkers & Prevention, 
26(8), 1209-1218. 

James-McAlpine, J. M. (2019). Micronutrient 
supplementation and birth outcomes in South-East 
Queensland Griffith University. 

Jansen, T. A., Korevaar, T. I., Mulder, T. A., White, T., 
Muetzel, R. L., Peeters, R. P., & Tiemeier, H. (2019). 
Maternal thyroid function during pregnancy and 
child brain morphology: a time window-specific 
analysis of  a prospective cohort. The Lancet Diabetes 
& Endocrinology, 7(8), 629-637. 

Khan, M. A., Ahsan, T., Rehman, U. L., Jabeen, R., & 
Farouq, S. (2017). Subclinical Hypothyroidism: 
Frequency, clinical presentations and treatment 
indications. Pakistan Journal of  Medical Sciences, 33(4), 
818. 

Kim, W. G., Kim, W. B., Woo, G., Kim, H., Cho, Y., Kim, 
T. Y., Kim, S. W., Shin, M.-H., Park, J. W., & Park, H.-L. 
(2017). Thyroid stimulating hormone reference range 
and prevalence of  thyroid dysfunction in the Korean 
population: Korea National Health and Nutrition 
Examination Survey 2013 to 2015. Endocrinology and 
Metabolism, 32(1), 106-114. 

Korevaar, T. I., Medici, M., Visser, T. J., & Peeters, R. P. 
(2017). Thyroid disease in pregnancy: new insights 
in diagnosis and clinical management. Nature Reviews 
Endocrinology, 13(10), 610-622. 

LeBeau, S. O., & Mandel, S. J. (2006). Thyroid disorders 
during pregnancy. Endocrinology and Metabolism Clinics, 
35(1), 117-136. 

Leung, A. S., Millar, L. K., Koonings, P. P., Montoro, 
M., & Mestman, J. H. (1993). Perinatal outcome in 
hypothyroid pregnancies. Obstetrics & Gynecology, 
81(3), 349-353. 

Li, C., Peng, S., Zhang, X., Xie, X., Wang, D., Mao, J., 
Teng, X., Shan, Z., & Teng, W. (2016). The urine 
iodine to creatinine as an optimal index of  iodine 
during pregnancy in an iodine adequate area in China. 
The Journal of  Clinical Endocrinology & Metabolism, 
101(3), 1290-1298. 

Malti, N. N. Frequency of  Subclinical Gestational Thyroid 
Function Abnormalities It’s Impact on Obstetrical 
Outcomes.

Mandel, S. J. (2004). Hypothyroidism and chronic 
autoimmune thyroiditis in the pregnant state: maternal 
aspects. Best Practice & Research Clinical Endocrinology & 
Metabolism, 18(2), 213-224. 

Mansouri, A., Norouzi, S., Sharifi, A., YektaKooshali, M. 
H., & Azami, M. (2017). The relationship of  maternal 
subclinical hypothyroidism during pregnancy and 
preterm birth: a systematic review and meta-analysis 
of  cohort studies. The Iranian Journal of  Obstetrics, 
Gynecology and Infertility, 19(40), 69-78. 

Maraka, S., Ospina, N. M. S., O’Keeffe, D. T., Espinosa 
De Ycaza, A. E., Gionfriddo, M. R., Erwin, P. J., 

Coddington III, C. C., Stan, M. N., Murad, M. H., & 
Montori, V. M. (2016). Subclinical hypothyroidism 
in pregnancy: a systematic review and meta-analysis. 
Thyroid, 26(4), 580-590. 

Marwaha, R., Tandon, N., Gupta, N., Karak, A., Verma, 
K., & Kochupillai, N. (2003). Residual goitre in the 
postiodization phase: iodine status, thiocyanate 
exposure and autoimmunity. Clinical Endocrinology, 
59(6), 672-681. 

Morreale de Escobar, G. (1998). The hypothyroxinemia 
of  prematurity. The Journal of  Clinical Endocrinology & 
Metabolism, 83(2), 713-715. 

Morreale de Escobar, G., Jesús Obregón, M. a., & Escobar 
del Rey, F. (2000). Is neuropsychological development 
related to maternal hypothyroidism or to maternal 
hypothyroxinemia? The Journal of  Clinical Endocrinology 
& Metabolism, 85(11), 3975-3987. 

Mullur, R., Liu, Y.-Y., & Brent, G. A. (2014). Thyroid 
hormone regulation of  metabolism. Physiological 
reviews. 

Obstetricians ACo, G. (2015). Practice bulletin No. 148: 
thyroid disease in pregnancy. Obstet Gynecol, 125(4), 
996. 

Pokhanna, J., Gupta, U., Alwani, M., & Tiwari, S. P. 
(2017). Prevalence of  thyroid dysfunction and impact 
on maternal and fetal outcome in central Indian 
pregnant women. International Journal of  Reproduction, 
Contraception, Obstetrics and Gynecology, 6(10), 4666-4671. 

Rosario, P. W., Oliveira, L. F. F., & Calsolari, M. R. (2018). 
Maternal hypothyroxinemia in the first trimester of  
gestation and association with obstetric and neonatal 
outcomes and iron deficiency: a prospective Brazilian 
study. Archives of  Endocrinology and Metabolism, 62, 332-
336. 

Sahu, M. T., Das, V., Mittal, S., Agarwal, A., & Sahu, M. 
(2010). Overt and subclinical thyroid dysfunction 
among Indian pregnant women and its effect on 
maternal and fetal outcome. Archives of  Gynecology and 
Obstetrics, 281, 215-220. 

Sakr, M. F., & Sakr, M. F. (2020). Thyroid Disease During 
Pregnancy. Springer. 

Shahid, M. A., Ashraf, M. A., & Sharma, S. (2018). 
Physiology, thyroid hormone. 

Sheehan, P. M., Nankervis, A., Araujo Júnior, E., & Da 
Silva Costa, F. (2015). Maternal thyroid disease and 
preterm birth: systematic review and meta-analysis. 
The Journal of  Clinical Endocrinology & Metabolism, 
100(11), 4325-4331. 

Sorrenti, S., Baldini, E., Pironi, D., Lauro, A., D’Orazi, 
V., Tartaglia, F., Tripodi, D., Lori, E., Gagliardi, F., & 
Praticò, M. (2021). Iodine: Its role in thyroid hormone 
biosynthesis and beyond. Nutrients, 13(12), 4469. 

Syamala, C., Amrutha, K., Swetha, B., & Padmavati, T. 
Prevalence Of  Hypothyroidism In Singleton Pregnant 
Women And Perinatal Outcome Using Tsh Levels As 
A Screening Tool. 

Taylor, P. N., Okosieme, O. E., Dayan, C. M., & Lazarus, 
J. H. (2014). Therapy of  endocrine disease: impact of  

https://journals.e-palli.com/home/index.php/ajcp


Pa
ge

 
8

https://journals.e-palli.com/home/index.php/ajcp

Am. J. Chem. Pharm. 2(2) 1-8, 2023

iodine supplementation in mild-to-moderate iodine 
deficiency: systematic review and meta-analysis. 
European Journal of  Endocrinology, 170(1), 1-15. 

Teng, X., Shan, Z., Chen, Y., Lai, Y., Yu, J., Shan, L., Bai, 
X., Li, Y., Li, N., & Li, Z. (2011). More than adequate 
iodine intake may increase subclinical hypothyroidism 
and autoimmune thyroiditis: a cross-sectional study 
based on two Chinese communities with different 
iodine intake levels. European Journal of  Endocrinology, 
164(6), 943-950. 

Unnikruishnan, A., Kalra, S., Sahay, R., Bantwal, G., 
Jhon, M., & Tewari, N. (2013). La prevalencia de 
hipotiroidismo en adultos; un estudio epidemiológico 
en ocho ciudades de la india. India Diario de 
Endocrinología y Metabolismo, 17(4), 647-652. 

Vannucchi, G., Covelli, D., Vigo, B., Perrino, M., Mondina, 
L., & Fugazzola, L. (2017). Thyroid volume and 
serum calcitonin changes during pregnancy. Journal of  
Endocrinological Investigation, 40, 727-732. 

Wade, A. N., & Mandel, S. J. (2018). Thyroid disease 
and pregnancy. In Medical Management of  Thyroid 
Disease 275-296. CRC Press. 

Wasserstrum, N., & Ananla, C. A. (1995). Perinatal 
consequences of  maternal hypothyroidism in early 
pregnancy and inadequate replacement. Clinical 
Endocrinology, 42(4), 353-358. 

Ziegler, G. M., Slaughter, J. L., Chaudhari, M., Singh, 
H., Sánchez, P. J., & Bunch, D. R. (2022). Preterm 
to term infant postmenstrual age reference intervals 
for thyroid-stimulating hormone and free thyroxine. 
Pediatric Research, 91(5), 1130-1135. 

Zimmermann, M. B. (2007). The adverse effects of  mild-
to-moderate iodine deficiency during pregnancy and 
childhood: a review. Thyroid, 17(9), 829-835. 

Zimmermann, M. B. (2016). The importance of  adequate 
iodine during pregnancy and infancy. Hidden Hunger, 
115, 118-124. 

https://journals.e-palli.com/home/index.php/ajcp

